Alnylam Pharmaceuticals Inc. (ALNY)

94.33
0.40 0.42
NASDAQ : Health Technology
Prev Close 94.73
Open 94.73
Day Low/High 93.11 / 95.87
52 Wk Low/High 50.39 / 153.99
Volume 706.22K
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 100.17M
Market Cap 9.60B
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present new results from the Phase 1 and Phase 1/2 open-label extension...

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi...

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran...

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17 th Annual Needham Healthcare Conference on Wednesday,...

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment...

HATTR Amyloidosis Fact Sheet

HATTR Amyloidosis Fact Sheet

For many people living with a rare disease, such as hereditary ATTR (hATTR) amyloidosis, it can take years to be accurately diagnosed.

Alnylam Retains Global Rights To Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Retains Global Rights To Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran (ALN-GO1), an...

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen and Company...

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2017 and highlighted recent progress in...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20 th Annual BIO CEO...

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February...

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated its...

Alnylam Announces 2018 Corporate Goals

Alnylam Announces 2018 Corporate Goals

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced its corporate goals for 2018.

Alnylam And Sanofi Enter Into Strategic Restructuring Of RNAi Therapeutics Rare Disease Alliance

Alnylam And Sanofi Enter Into Strategic Restructuring Of RNAi Therapeutics Rare Disease Alliance

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development...

Alnylam Expands Alnylam Act™ Program To Include No-Charge Third-Party Genetic Testing And Counseling For People At Risk For Acute Hepatic Porphyrias

Alnylam Expands Alnylam Act™ Program To Include No-Charge Third-Party Genetic Testing And Counseling For People At Risk For Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has expanded the Alnylam Act™ program to include no-charge, third-party genetic testing and counseling for...

Alnylam To Webcast Presentation At 36th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 36th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36 th Annual J.

Alnylam To Webcast Presentation At Goldman Sachs Healthcare CEOs Unscripted Conference

Alnylam To Webcast Presentation At Goldman Sachs Healthcare CEOs Unscripted Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday,...

Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the submission of a Marketing Authorisation...

FDA Lifts Clinical Hold On Fitusiran

FDA Lifts Clinical Hold On Fitusiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the U.

Alnylam Completes Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Completes Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.

Alnylam Announces Expansion Of U.S. Orphan Drug Designation For Patisiran To Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Announces Expansion Of U.S. Orphan Drug Designation For Patisiran To Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the U.

Alnylam To Webcast Presentation At BMO Capital Markets Prescriptions For Success Healthcare Conference

Alnylam To Webcast Presentation At BMO Capital Markets Prescriptions For Success Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare...

U.S. Food And Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis With Polyneuropathy

U.S. Food And Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.

Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of its previously announced underwritten registered public offering of 6,440,000 shares of its common stock,...

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.

TheStreet Quant Rating: D (Sell)